Prevalence of mild cognitive impairment and its subtypes in the Heinz Nixdorf Recall study cohort

Martha Dlugaj1, Christian Weimar, Natalia Wege

  • 1Department of Neurology, University Hospital Essen, Essen, Germany. Martha.Dlugaj@uk-essen.de

Abstract

Insights

Prevalence of mild cognitive impairment (MCI) is high in older adults, with modified criteria identifying more cases. Subtype prevalence and associated factors like age and education differ based on the criteria used.

Area of Science:

  • Gerontology and Cognitive Neurology
  • Epidemiology of Neurodegenerative Diseases

Background:

  • Mild cognitive impairment (MCI) is a transitional stage between normal aging and dementia.
  • Accurate prevalence estimation of MCI is crucial for understanding population health and planning interventions.

Purpose of the Study:

  • To investigate the prevalence of mild cognitive impairment (MCI) using both original and modified Petersen criteria.
  • To compare the subtypes of MCI and their associations with demographic factors under different diagnostic criteria.

Main Methods:

  • A German population-based study included 4,145 subjects aged 50-80 years.
  • Cognitive screening was followed by detailed neuropsychological evaluation in selected participants.
  • Prevalence was estimated using bias correction, and logistic regression analyzed associations with age, gender, and education.

Main Results:

  • MCI prevalence was 7.8% with original criteria and 12.1% with modified criteria.
  • Amnestic MCI subtypes were more prevalent under modified criteria (7.8% vs. 4.3%).
  • MCI prevalence was associated with older age, lower education, and gender, varying by criteria.

Conclusions:

  • Prevalence rates of MCI are substantial in the general population.
  • The choice of diagnostic criteria significantly impacts MCI prevalence and subtype distribution.
  • Understanding these variations is key for accurate epidemiological assessment and clinical management.

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...